Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post Polycythemia Vera Myelofibrosis”

160 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 160 results

Not applicableNot Yet RecruitingNCT06785870
What this trial is testing

EVAluation of Erythrocytosis PRospEctive Cohort STudy

Who this might be right for
ErythrocytosisPolycythemiaPolycythemia Secondary+5 more
Cyrus Hsia 1,500
Testing effectiveness (Phase 2)Study completedNCT01423058
What this trial is testing

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 61
Testing effectiveness (Phase 2)WithdrawnNCT04354727
What this trial is testing

APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Who this might be right for
Myelofibrosis
Ascentage Pharma Group Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Testing effectiveness (Phase 2)Ended earlyNCT02421354
What this trial is testing

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Who this might be right for
HepatomegalyMyelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+2 more
M.D. Anderson Cancer Center 8
Not applicableEnded earlyNCT00726830
What this trial is testing

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more
M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT00669578
What this trial is testing

CC-4047 in Treating Patients With Myelofibrosis

Who this might be right for
Chronic Myeloproliferative DisordersSecondary Myelofibrosis
Mayo Clinic 77
Testing effectiveness (Phase 2)Study completedNCT00089011
What this trial is testing

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+171 more
Fred Hutchinson Cancer Center 150
Testing effectiveness (Phase 2)Study completedNCT01420770
What this trial is testing

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 30
Early research (Phase 1)Ended earlyNCT02436135
What this trial is testing

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Who this might be right for
Myelofibrosis
Gilead Sciences 10
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Not applicableWithdrawnNCT00499668
What this trial is testing

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Who this might be right for
Myeloproliferative DisordersLeukemiaLymphoma+5 more
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Study completedNCT04884191
What this trial is testing

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost- Essential Thrombocythemia Myelofibrosis
CTI BioPharma 165
Large-scale testing (Phase 3)Ended earlyNCT04551066
What this trial is testing

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 252
Testing effectiveness (Phase 2)UnknownNCT04640532
What this trial is testing

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+1 more
Kartos Therapeutics, Inc. 116
Testing effectiveness (Phase 2)Study completedNCT02556931
What this trial is testing

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSmall Lymphocytic Lymphoma+11 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 117
Testing effectiveness (Phase 2)Study completedNCT04218071
What this trial is testing

Actuate 1901: 9-ING-41 in Myelofibrosis

Who this might be right for
Myelofibrosis
Actuate Therapeutics Inc. 17
Early research (Phase 1)WithdrawnNCT04283526
What this trial is testing

Study of Select Combinations in Adults With Myelofibrosis

Who this might be right for
Primary MyelofibrosisMyelofibrosisPMF+2 more
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT02493530
What this trial is testing

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Who this might be right for
MyelofibrosisPolycythemia Vera
Vanderbilt-Ingram Cancer Center 60
Early research (Phase 1)Study completedNCT01317875
What this trial is testing

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Who this might be right for
Myelofibrosis
Incyte Corporation 69
Next Page